my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Collaboration between the Immanuel Klinikum Bernau Herzzentrum Brandenburg, the Rheumazentrum Nord-Brandenburg and BioTeZ demonstrates new ways of treating rheumatoid arthritis. Through the introduction of therapeutic antibodies, the treatment results for rheumatoid arthritis (RA) have been signific more
AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology company developing monoclonal antibody (MAb) biosimilars have entered into an agreement for the co-development of a biosimilar more
UCB announced the start of the EXXELERATE™ study which will evaluate the short- and long-term efficacy of Cimzia® (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira®* (adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this stud more
Adalimumab Adalimumab (brand name Humira) is the third TNF antagonist, after infliximab and etanercept , to be approved in the U.S. Like infliximab and etanercept, adalimumab binds to TNFα , preventing it from activating TNF receptors; adalim ... more
Watchlist
This is where you can add this topic to your personal favourites
© 1997-2024 LUMITOS AG, All rights reserved
